Kent Ahmet Muhtar
Known title: DirectorCIK: 0001324132
Associated companies
Transaction History
| MMM | ▲ Buy | Grant | 368 | $39K | 4/28/2023 | View on chart |
| MMM | ▲ Buy | Grant | 341 | $39K | 1/27/2023 | View on chart |
| MMM | ▲ Buy | Grant | 316 | $39K | 10/28/2022 | View on chart |
| MMM | ▲ Buy | Grant | 276 | $39K | 7/29/2022 | View on chart |
| MMM | ▲ Buy | Grant | 1,214 | $185K | 5/10/2022 | View on chart |
| MMM | ▲ Buy | Grant | 263 | $39K | 4/29/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
3M to challenge $1.4B Australian PFAS lawsuit ahead of Q3 earnings
3M is preparing to challenge Australia's $1.4 billion PFAS contamination lawsuit, a major legal development for the company. At the same time, market participants are looking ahead to 3M's upcoming third-quarter earnings, with Wall Street projections offering insights into key metrics. The stock is currently trading within its 52-week range, with an average analyst target of $186.15.
3M to challenge $1.4B Australian PFAS lawsuit ahead of Q3 earnings. 3M is preparing to challenge Australia's $1.4 billion PFAS contamination lawsuit, a major legal development for the company. At the same time, market participants are looking ahead to 3M's upcoming third-quarter earnings, with Wall Street projections offering insights into key metrics. The stock is currently trading within its 52-week range, with an average analyst target of $186.15.